NUT midline carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0060463
Name NUT midline carcinoma
Definition A carcinoma that is characterized by a BRD4-NUT translocation involving the rearrangement of the bromodomain-containing protein 4 (BRD4) and the gene encoding nuclear protein of the testis (NUT) at 15q14, BRD4-NUT t(15;19)(q14;q13.1) and arises from midline epithelial structures, most commonly the head, neck, and mediastinum.
Source DiseaseOntology.org
Alt Ids
Xrefs
SNOMEDCT_US_2023_03_01:733922002
Path disease disease of cellular proliferation cancer cell type cancer carcinoma NUT midline carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01987362 Phase I TEN-010 A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Completed USA 0
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed USA 0
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Completed USA | FRA | ESP | DEU | BEL 1
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated 0
NCT03936465 Phase I BMS986158 CC-90010 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Completed USA | CAN 0
NCT04718675 Phase Ib/II KB-0742 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) Terminated USA | GBR | ESP 0
NCT05019716 Phase I ZEN-3694 Cisplatin + Etoposide + ZEN-3694 Carboplatin + Paclitaxel + ZEN-3694 Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma Recruiting USA 0
NCT05372640 Phase I Abemaciclib + ZEN-3694 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors Recruiting USA 0
NCT05488548 Phase I NEO2734 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors Recruiting USA 0
NCT06943521 Phase Ib/II MT-4561 A Study of MT-4561 in Patients With Various Advanced Solid Tumors Recruiting USA 1
NCT07050186 Phase II Cemiplimab Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma Recruiting USA 0